Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi SA (NASDAQ: SNY) has announced new study data of Soliqua 100/33 (insulin glargine and lixisenatide injection) that met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed insulin in type 2 diabetes. The data were presented at the American Diabetes Association's 81st Scientific Sessions.

Sanofi's Soliqua Shows Improved Blood Sugar Control Without Weigh Gain Against Premixed Insulin

Regeneron Pharmaceuticals

Regeneron (REGN) and partner Sanofi win EC approval for Libtayo for skin cancer and lung cancer.

Regeneron (REGN)/Sanofi's Libtayo Approved for Additional Indications

The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two additional indications - basal cell carcinoma (BCC) and non-small cell lung cancer with over 50% PD-L1 expression. BCC (skin cancer) approval covers adults with locally advanced or metastatic disease who have progressed on or are intolerant to a hedgehog pathway inhibitor.

Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings

Availability of the Q2 2021 Memorandum for modelling purposes

Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes

Telesis Bio Inc

Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.

Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine

Sanofi SA (SNY) at Guggenheim Biopharma Strategy Series Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation Conference (Transcript)

Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza. The 280-subject trial will assess the safety and immunogenicity (immune response) of the monovalent (single-strain) mRNA-based flu vaccine candidate.

Sanofi, Translate Bio Initiate Early-Stage mRNA Influenza Vaccine Trial

-- Trial will evaluate potential of next generation of influenza vaccines with combined mRNA technology and flu vaccine development expertise -- -- Positive preclinical safety and immunogenicity data for mRNA influenza vaccine candidates support initiation of Phase 1 clinical trial --

Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine

The European Commission approves Sanofi's (SNY) Aubagio for the treatment of pediatric patients aged 10 to 17 years with relapsing-remitting multiple sclerosis.

Sanofi's (SNY) Aubagio Gets EU Nod for MS in Pediatric Patients

The European Commission has approved Sanofi SA's (NASDAQ: SNY) Aubagio (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS). The EC approval is based on data from the Phase 3 TERIKIDS study.

Europe Approves Sanofi's Expanded Use Of Aubagio In Pediatric Patients With Multiple Sclerosis

The FDA has approved Sanofi SA's (NASDAQ: SNY) newly completed plant in Swiftwater, Pennsylvania. The license will allow Sanofi to begin production of its Fluzone High-Dose vaccine for the 2021-22 flu season.

Sanofi Scores FDA Approval For Flu-Shot Facility In US

Sanofi SA's (NASDAQ: SNY) sutimlimab nailed all three of its primary endpoints in its Phase 3 CADENZA study for patients with cold agglutinin disease. This rare disorder can cause severe anemia without a recent history of blood transfusion.

Sanofi's Sutimlimab Hits Endpoint Goal In Rare Anemia Study After FDA Rejection

Sanofi SA (SNY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

Amgen

AstraZeneca

BeiGene

Legend Biotech

A recent regulatory overhaul designed to speed up development and approval of new drugs in China has been welcomed by global pharma giants and local startups alike, aimed at bringing their latest cutting-edge treatments more quickly to Chinese patients.

Drug Startups Eye Quicker Profits Under China's New Fast-Track Approvals

Sanofi launches its new global employee share ownership plan

Sanofi (SNY) Management Presents on 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Conference (Transcript)

Sanofi SA (NASDAQ: SNY) has secured partners for a Phase 3 trial to study amcenestrant versus the hormone therapy tamoxifen in breast cancer. The Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC), and the Alliance Foundation Trials (AFT) will initiate the pivotal trial.

Sanofi Inks Partnership for Late-Stage Trial of Amcenestrant as Add-On Breast Cancer Therapy

PARIS, June 4, 2021 /PRNewswire/ -- Sanofi is partnering with leading groups delivering practice-changing breast cancer research, the Breast International Group (BIG), the European Organization for Research and Treatment of Cancer (EORTC) and the Alliance Foundation Trials (AFT), to initiate a pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting. The Phase 3 AMEERA-6 study will evaluate the efficacy and safety of Sanofi's amcenestrant vs tamoxifen for women with estrogen receptor-positive (ER+) breast cancer who were unable to continue their adjuvant aromatase inhibitor (AI) therapy.

Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

Ocugen, Inc.

Valneva SE

Arcturus Therapeutics

CureVac B.V

Novavax

Dr. Reddy's Labs

These Covid-19 vaccine stocks may be late in the race, but they certainly have growth potential as we head into the summer. The post 7 Best Vaccine Stocks for Their Pipeline Potential appeared first on InvestorPlace.

7 Best Vaccine Stocks for Their Pipeline Potential

The White House said Thursday that it removed a requirement that is part of the Defense Production Act that gives the U.S. preferential orders for the COVID-19 vaccines developed by AstraZeneca , Novavax Inc. , and Sanofi . None of these shots have been authorized in the U.S., but the change allows the companies to decide which orders, including from other countries, they will fulfill first.

White House to allow AstraZeneca, Novavax, Sanofi to distribute COVID-19 shots how they see fit

Sanofi l aunches € 3 million Planet Mobilization f und to support employees' environmental projects

Sanofi launches €3 million Planet Mobilization fund to support employees' environmental projects

AllianceBernstein Hld

Sanofi's (SNY) Management on Alliance Bernstein 37th Annual Strategic Decisions Conference - Transcript

Sanofi (SNY) discontinues development of pipeline candidate, venglustat, in patients with autosomal dominant polycystic kidney disease, following failure in a pivotal study.

Sanofi (SNY) Stops Venglustat Development as Kidney Cyst Drug

Sanofi SA (NASDAQ: SNY) has halted the clinical program of venglustat in autosomal dominant polycystic kidney disease (ADPKD). Although the safety profile of venglustat remains consistent with previously reported results, the Phase 2/3 STAGED-PKD study of the drug did not meet its futility criteria.

Sanofi Stops Venglustat Development In Rare Genetic Kidney Disorder

Sanofi provides update on venglustat clinical program

News for Sanofi Stock (SNY)